| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD010952.PUB2 |
| P698 | PubMed publication ID | 26186173 |
| P50 | author | Rachelle Buchbinder | Q28036349 |
| Louise Falzon | Q38321839 | ||
| Sofia Ramiro | Q39184066 | ||
| Désirée van der Heijde | Q47262835 | ||
| P2093 | author name string | Féline PB Kroon | |
| Lennart RA van der Burg | |||
| Robert BM Landewé | |||
| P2860 | cites work | Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) | Q24201300 |
| Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 | ||
| Grading quality of evidence and strength of recommendations | Q24562409 | ||
| Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis | Q24601392 | ||
| 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis | Q24603648 | ||
| Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials | Q24619410 | ||
| Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis | Q24674389 | ||
| The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 | ||
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis | Q28363578 | ||
| Double-bind cross-over tiral of flurbiprofen and phenylbutazone in ankylosing spondylitis | Q28363614 | ||
| Cyclooxygenases 1 and 2 | Q29615645 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug | Q32045021 | ||
| Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis | Q33551403 | ||
| A comparative study of Butacote and Naprosyn in ankylosing spondylitis | Q33551605 | ||
| Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis | Q33964496 | ||
| The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy | Q34016674 | ||
| Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria | Q34055060 | ||
| Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis | Q34270783 | ||
| Isoxicam vs ketoprofen in ankylosing spondylitis | Q34447439 | ||
| Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration | Q34527487 | ||
| Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study | Q34580931 | ||
| Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. | Q34621619 | ||
| Oxaprozin versus diclofenac sodium in the treatment of ankylosing spondylitis | Q34687790 | ||
| Sulindac in ankylosing spondylitis. Double-blind evaluation of sulindac and indomethacin | Q34700166 | ||
| A comparative study of diclofenac and sulindac in ankylosing spondylitis | Q34714327 | ||
| Sulindac and indomethacin in the treatment of ankylosing spondylitis: a double-blind cross-over study | Q34718355 | ||
| Renal toxicity of the nonsteroidal anti-inflammatory drugs | Q34731188 | ||
| Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair | Q34792085 | ||
| Selective COX-2 Inhibitors and Dual Acting Anti-inflammatory Drugs: Critical Remarks | Q35122494 | ||
| Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort | Q35165774 | ||
| Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis | Q35553458 | ||
| Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis | Q35554988 | ||
| Epidemiology of spondyloarthritis | Q35750729 | ||
| The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? | Q36092954 | ||
| Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study | Q36247207 | ||
| Evaluation of the quality of prognosis studies in systematic reviews | Q36426632 | ||
| Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease | Q36677345 | ||
| Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years | Q37350944 | ||
| Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. | Q37465472 | ||
| Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis | Q37723103 | ||
| 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis | Q37871699 | ||
| First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis | Q38003531 | ||
| A wider spectrum of spondyloarthropathies | Q38003622 | ||
| Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons | Q38517756 | ||
| Treatment of ankylosing spondylitis with flurbiprofen and indomethacin | Q39457426 | ||
| Treatment of ankylosing spondylitis with flurbiprofen or phenylbutazone | Q39582415 | ||
| NSAID-induced gastroduodenal damage: is prevention needed? A review and metaanalysis. | Q40618281 | ||
| A trial of feprazone in ankylosing spondylitis | Q40814171 | ||
| Efficacy of diclofenac in ankylosing spondylitis | Q42217024 | ||
| The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Français d'Etude Génétique des Spondylarthropathies | Q42628076 | ||
| Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life | Q43789921 | ||
| MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib | Q46295007 | ||
| Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study | Q46428507 | ||
| Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial | Q46525954 | ||
| Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. | Q47968602 | ||
| Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept | Q48533541 | ||
| A stratified model for health outcomes in ankylosing spondylitis | Q48623216 | ||
| The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. | Q51848128 | ||
| The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. | Q51848130 | ||
| Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. | Q52864698 | ||
| The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. | Q52911182 | ||
| Ankylosing spondylitis | Q54165668 | ||
| Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis | Q61628500 | ||
| Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study | Q61628505 | ||
| Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. | Q64979798 | ||
| A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis | Q67282948 | ||
| Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs | Q67903664 | ||
| A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis | Q68889078 | ||
| Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients | Q69864194 | ||
| Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with phenylbutazone | Q70040300 | ||
| Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with indomethacin | Q70040302 | ||
| Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis | Q70322030 | ||
| A double-blind cross-over trial of indomethacin, fenoprofen and placebo in ankylosing spondylitis, with comments on patient assessment | Q72146256 | ||
| Diagnostic features of ankylosing spondylitis | Q72329674 | ||
| Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs | Q72674958 | ||
| Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study | Q72838995 | ||
| A nonsteroidal anti-inflammatory agent. Indomethacin (indocin) | Q72885712 | ||
| Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial | Q73224851 | ||
| Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases | Q74060229 | ||
| Undifferentiated spondyloarthropathies: a 2-year follow-up study | Q74127478 | ||
| Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis | Q74384586 | ||
| Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study | Q77583006 | ||
| What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter | Q80502420 | ||
| Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis | Q82097915 | ||
| Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores | Q82414520 | ||
| ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis | Q82854967 | ||
| ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis | Q85007143 | ||
| Tenoxicam compared with diclofenac in patients with ankylosing spondylitis | Q93510613 | ||
| P921 | main subject | ankylosing spondylitis | Q52849 |
| inflammation | Q101991 | ||
| P577 | publication date | 2015-07-17 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) |
| Q37229557 | 25 Years Old Women With Inflammatory Low Back Pain |
| Q92576255 | Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study |
| Q39098003 | Axial spondyloarthritis. |
| Q33582869 | Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. |
| Q91710451 | Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis |
| Q33468052 | Effect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis |
| Q37601459 | Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis |
| Q89449421 | Inflammation: NSAIDs and cardiovascular risk in arthritis |
| Q30238960 | Medication Overuse in Chronic Pain |
| Q38799979 | New evidence on the management of spondyloarthritis. |
| Q89563793 | Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis |
| Q55285080 | Positives and negatives of nonsteroidal anti-inflammatory drugs in bone healing: the effects of these drugs on bone repair. |
| Q33841187 | The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels |
| Q59134860 | The current standard of care and the unmet needs for axial spondyloarthritis |
| Q38371958 | The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line. |
| Q39135959 | Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies. |
| Q35854185 | Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression. |
| Q59335179 | Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life |
Search more.